Odanacatib (MK-0822), a potent, orally-active inhibitor of cathepsin K, is under clinical development for treatment of postmenopausal osteoporosis. This poster describes base model development of a semi-mechanistic model of bone turnover to describe creatinine adjusted urinary aminoterminal crosslinked telopeptides of Type I collagen (uNTx), a bone resorption biomarker, and lumbar spine bone mineral density (LS-BMD) data from two Phase II dose-ranging studies during and after treatment with odanacatib.
International Symposium on Measurement and Kinetics of In Vivo Drug Effects, Noordwijkerhout, The Netherlands, April 2010
By Julie A. Stone, David Jaworowicz, Stefan Zajic, Albert Leung, Le Thi Duong, Julie Passarell, Jill Fiedler-Kelly, Dosinda Cohn, Nadia Verbruggen, and Aubrey Stoch